Replies to post #2128 on Akers Biosciences Inc. (AKER)

[knuts4oe]

Thanks for posting. Looks like competition heating up for MyMD Pharma/Johns Hopkins. Wonder what the patent situation is!

[leifsmith]

Extremely interesting!

I just sent this info to a very capable and unconventional doctor:

Taming the adverse effects of excessive NF-?B seems to be important.

"Anatabine has been shown to inhibit lipopolysaccharide (LPS)-induced pro-inflammatory gene expression as well as NF-?B and STAT3 phosphorylation in human neuroblastoma SH-SY5Y, HEK293, human microglia, and human blood mononuclear cells [33] as well as in the brain and spleen of mouse models of autoimmune encephalomyelitis [31] and Alzheimer’s disease [33]. In SH-SY5Y cells, anatabine also reduced the expression of beta-secretase 1—the rate limiting enzyme for ß-amyloid peptide production, which is a major hallmark of Alzheimer’s disease—through inhibition of NF-?B activation [21].”

Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis
https://journal-inflammation.biomedcentral.com/articles/10.1186/s12950-020-00260-6

The authors of this paper all seem affiliated with Philip Morris. That company acquired the relevant patents from a company destroyed by the FDA (for no good reason that I could see). Since that time, the product forced off the market by the FDA, has not reappeared. I know people whose lives were damaged significantly by the forced withdrawal of the product, Anatabloc.

All this started when it was noticed that airline stewardesses exposed to second-hand smoke seemed to be less likely to suffer from thyroiditis.

This paper, by Patrizio Caturegli at Johns Hopkins resulted:
"Anatabine ameliorates experimental autoimmune thyroiditis"
https://pubmed.ncbi.nlm.nih.gov/22807490/

Happy 2021!